

CURIS INC
Form 3/A
February 27, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â RA CAPITAL MANAGEMENT, LLC			(Month/Day/Year)	CURIS INC [CRIS]	
(Last)	(First)	(Middle)	08/08/2007		
C/O RA CAPITAL MANAGEMENT, LLC, Â 111 HUNTINGTON AVE., SUITE 610			4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)		08/15/2007
BOSTON, Â MA Â 02199			<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
(City)	(State)	(Zip)			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,550,564	I	See Footnote <u>(1)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date	3. Title and Amount of Securities Underlying	4. Conversion	5. Ownership	6. Nature of Indirect Beneficial Ownership
---	---	--	---------------	--------------	--

Edgar Filing: CURIS INC - Form 3/A

(Month/Day/Year)	Derivative Security (Instr. 4)	or Exercise Price of Derivative Security	Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
RA CAPITAL MANAGEMENT, LLC C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVE., SUITE 610 BOSTON, MA 02199	^	^ X	^	^
ALDRICH RICHARD C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVE., SUITE 610 BOSTON, MA 02199	^	^ X	^	^
Kolchinsky Peter C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVE., SUITE 610 BOSTON, MA 02199	^	^ X	^	^
RA Capital Biotech Fund LP C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVE., SUITE 610 BOSTON, MA 02199	^	^ X	^	^
RA Capital Biotech Fund II, L.P. C/O RA CAPITAL MANAGEMENT, LLC 111 HUNTINGTON AVE., SUITE 610 BOSTON, MA 02199	^	^ X	^	^

Signatures

/s/ Peter Kolchinsky, Manager of RA Capital Management, LLC	02/27/2008
**Signature of Reporting Person	Date
Richard H. Aldrich	02/27/2008
**Signature of Reporting Person	Date
Peter Kolchinsky	02/27/2008
**Signature of Reporting Person	Date
Peter Kolchinsky, Manager of RA Capital Management, LLC, the General Partner of RA Capital Biotech Fund, L.P.	02/27/2008
**Signature of Reporting Person	Date
Peter Kolchinsky, Manager of RA Capital Management, LLC, the General Partner of RA Capital Biotech Fund II, L.P.	02/27/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) 1. Includes 29,472 shares held by RA Capital Biotech Fund, L.P. ("Fund I") and 528 shares held by RA Capital Biotech Fund II, L.P. ("Fund II") that were inadvertently omitted from the reporting persons' original Form 3. These shares were held prior to an acquisition of stock and warrants made by Fund I and Fund II on August 8, 2007. Currently, Fund I holds 7,417,674 shares and Fund II holds 132,890 shares. RA Capital Management, LLC (the "General Partner") is the general partner of each of Fund I and Fund II, and Richard H. Aldrich and Peter Kolchinsky are the sole managers of the General Partner. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein, if any.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.